XW-004 is under clinical development by Sciwind Biosciences and currently in Phase I for Type 2 Diabetes. According to GlobalData, Phase I drugs for Type 2 Diabetes have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how XW-004’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
XW-004 is under development for the treatment of nonalcoholic steatohepatitis (NASH), liver fibrosis, obesity and type 2 diabetes. It is administered through oral route. The drug candidate acts by targeting glucagon like peptide 1 (GLP1). The drug candidate is being developed based on polypeptide or recombinant protein preparation platform technology.
Sciwind Biosciences overview
Sciwind Biosciences is a drug research and development company for metabolic diseases that contain protein and peptide candidates for non-alcoholic steatohepatitis. Sciwind Biosciences is headquartered in Hangzhou, Zhejiang, China.
For a complete picture of XW-004’s drug-specific PTSR and LoA scores, buy the report here.